<DOC>
	<DOCNO>NCT01266707</DOCNO>
	<brief_summary>The purpose study assess toxicity angiogenic peptide vaccine therapy treat HLA-A*2402 restrict patient advanced hepatocellular carcinoma .</brief_summary>
	<brief_title>Antiangiogenic Peptide Vaccine Therapy Treating Patient With Hepatocellular Carcinoma</brief_title>
	<detailed_description>It require develop new treatment modality patient advance heptatocellular carcinoma . Immunotherapy one encourage modality patient . We assess toxicity , clinical response immune responsiveness .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Angiogenesis Inhibitors</mesh_term>
	<criteria>Unresectable treatmentresistant patient Hepatocellular carcinoma Measurable disease CT scan ECOG performance status 02 Life expectancy &gt; 3 month Laboratory value follow : 2,000/mm3 &lt; WBC &lt; 15,000/mm3 , Platelet count &gt; 75,000/mm3 , Total Bilirubin &lt; 1.5 mg/dl , Asparate transaminase &lt; 150IU/L , Alanine transaminase &lt; 150 IU/L , Creatinine &lt; 3.0mg/dl HLAA*2402 Able willing give valid write informed consent Pregnancy ( woman childbearing potential : Refusal inability use effective mean contraception ) Brestfeeder Active uncontrolled infection Steroids immunosuppressing agent dependent status Active uncontrolled malignancy Serious uncured wound Decision unsuitableness principal investigator physicianin charge</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Hepatocellular carcinoma</keyword>
	<keyword>peptide vaccine</keyword>
	<keyword>VEGFR</keyword>
</DOC>